Michael Yang, ViaCyte CEO
After years of failure, ViaCyte shows off first proof-of-concept for diabetes stem cell transplants
Seven years after they first tried it, ViaCyte finally has data showing that their stem cell treatment for diabetes — a potential cure — can work in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.